公开(公告)号：US20230365707A1

公开(公告)日：2023-11-16

申请号：US18134844

申请日：2023-04-14

申请人： BioNTech Research and Development, Inc.

发明人： Ritsuko Sawada ,  Shu-Man Sun ,  Wolfgang Scholz

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K51/10 ,  C07K16/30 ,  A61K39/00 ,  A61K31/337 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/2896 ,  C07K16/28 ,  A61K39/39533 ,  A61K45/06 ,  A61K51/1045 ,  A61K51/1057 ,  C07K16/3076 ,  A61K39/0011 ,  A61K31/337 ,  A61K39/39558 ,  A61K51/1027 ,  A61K51/1093 ,  G01N33/57438 ,  G01N33/577 ,  C07K2317/56 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  A61K2039/6081 ,  C07K2317/626

摘要： The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

公开(公告)号：US20230348605A1

公开(公告)日：2023-11-02

申请号：US18175786

申请日：2023-02-28

申请人： Massachusetts Institute of Technology ,  Children's Medical Center Corporation ,  Whitehead Institute for Biomedical Research

发明人： Richard O. Hynes ,  Noor Jailkhani ,  Hidde L. Ploegh ,  Yushu J. Xie

IPC分类号： C07K16/28 ,  A61P35/04 ,  A61K49/08 ,  A61K49/00 ,  A61K47/68 ,  A61K51/10 ,  C07K14/78 ,  C07K16/18

CPC分类号： C07K16/2842 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6849 ,  A61K47/6851 ,  A61K49/0058 ,  A61K49/085 ,  A61K51/1027 ,  A61K51/1045 ,  A61K51/1051 ,  A61K51/1057 ,  A61K51/1093 ,  A61P35/04 ,  C07K14/78 ,  C07K16/18 ,  B82Y5/00

摘要： Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.

公开(公告)号：US11679147B2

公开(公告)日：2023-06-20

申请号：US17853344

申请日：2022-06-29

申请人： Immatics Biotechnologies GmbH

发明人： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  A61K51/10 ,  A61K35/12

CPC分类号： A61K39/00111 ,  A61K35/17 ,  A61K38/04 ,  A61K39/0011 ,  A61K51/1057 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  G01N33/6803 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998

摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20170145092A1

公开(公告)日：2017-05-25

申请号：US15370711

申请日：2016-12-06

申请人： China Synthetic Rubber Corporation

发明人： Kuo-Jang Kao ,  Andrew T. Huang

IPC分类号： C07K16/28 ,  G01N33/577 ,  G01N33/574 ,  C07K16/30 ,  A61K51/10

CPC分类号： C07K16/28 ,  A61K39/39558 ,  A61K45/06 ,  A61K51/1018 ,  A61K51/1027 ,  A61K51/1057 ,  C07K16/303 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/21 ,  C12Q1/6886 ,  G01N33/57438 ,  G01N33/577 ,  G01N2333/47

摘要： The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.

公开(公告)号：US08728477B2

公开(公告)日：2014-05-20

申请号：US11902194

申请日：2007-09-19

申请人： Jean Kadouche ,  Emmanuelle Sabbah-Petrover ,  Olivier Chose

发明人： Jean Kadouche ,  Emmanuelle Sabbah-Petrover ,  Olivier Chose

IPC分类号： A61K39/395 ,  C07K16/18 ,  A61K51/10 ,  A61K39/00 ,  C07K16/30

CPC分类号： A61K51/1045 ,  A61K47/6851 ,  A61K51/1057 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/732

摘要： The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma.

摘要翻译： 本发明涉及识别人酸性和碱性异铁蛋白共有表位的单克隆，嵌合或人源化抗体或抗体样分子。 抗铁蛋白抗体或抗体样分子可以用于免疫治疗或放射免疫疗法的药物组合物中以靶向哺乳动物中的各种癌细胞。 还公开了将抗铁蛋白抗体或抗体样分子递送至癌性淋巴细胞，胰腺细胞，淋巴内皮细胞和肝细胞的方法，以及用于治疗胰腺癌，肝细胞癌，卡波西肉瘤和霍奇金淋巴瘤的方法。

公开(公告)号：US20130022539A1

公开(公告)日：2013-01-24

申请号：US13523393

申请日：2012-06-14

申请人： Glenn Pilkington ,  Gilbert-Andre Keller ,  Wenlu Li ,  Laura Corral ,  Iris Simon

发明人： Glenn Pilkington ,  Gilbert-Andre Keller ,  Wenlu Li ,  Laura Corral ,  Iris Simon

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P35/04 ,  A61K51/10 ,  G01N21/64 ,  C12N5/10 ,  C12N5/20 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  C07K16/40 ,  G01N33/577

CPC分类号： C07K16/3069 ,  A61K47/6825 ,  A61K47/6851 ,  A61K51/1051 ,  A61K51/1054 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3046 ,  C07K2317/73 ,  C07K2317/77

摘要： The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.

摘要翻译： 本发明提供在体内在哺乳动物细胞上结合Ovr115的分离的抗卵巢，胰腺，肺或乳腺癌抗原（Ovr115）抗体。 本发明还包括包含抗Ovr115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Ovr115抗体的分离的核酸，以及包含分离的核酸的表达载体。 还提供产生抗Ovr115抗体的细胞。 本发明包括产生抗Ovr115抗体的方法。 本发明的其它方面是杀死表达Ovr115的癌细胞的方法，包括使癌细胞与抗Ovr115抗体接触，以及减轻或治疗哺乳动物中表达Ovr115的癌症的方法，包括给予治疗有效量 的抗Ovr115抗体。

公开(公告)号：US08207311B2

公开(公告)日：2012-06-26

申请号：US10556478

申请日：2004-05-17

申请人： Glenn Pilkington ,  Gilbert-Andre Keller ,  Wenlu Li ,  Laura Corral ,  Iris Simon

发明人： Glenn Pilkington ,  Gilbert-Andre Keller ,  Wenlu Li ,  Laura Corral ,  Iris Simon

IPC分类号： C07K16/00 ,  C07K17/00 ,  C07K17/14 ,  C12P21/08 ,  A61K39/395 ,  A61K39/00 ,  G01N33/53 ,  G01N33/574 ,  C12N5/07 ,  C12N5/16

CPC分类号： C07K16/3069 ,  A61K47/6825 ,  A61K47/6851 ,  A61K51/1051 ,  A61K51/1054 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3046 ,  C07K2317/73 ,  C07K2317/77

摘要： The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.

摘要翻译： 本发明提供在体内在哺乳动物细胞上结合Ovr115的分离的抗卵巢，胰腺，肺或乳腺癌抗原（Ovr115）抗体。 本发明还包括包含抗Ovr115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Ovr115抗体的分离的核酸，以及包含分离的核酸的表达载体。 还提供产生抗Ovr115抗体的细胞。 本发明包括产生抗Ovr115抗体的方法。 本发明的其它方面是杀死表达Ovr115的癌细胞的方法，包括使癌细胞与抗Ovr115抗体接触，以及减轻或治疗哺乳动物中表达Ovr115的癌症的方法，包括给予治疗有效量 的抗Ovr115抗体。

公开(公告)号：US20110288278A1

公开(公告)日：2011-11-24

申请号：US13182492

申请日：2011-07-14

申请人： Hiroyuki Aburatani ,  Hiroko Iwanari ,  Isao Kohno

发明人： Hiroyuki Aburatani ,  Hiroko Iwanari ,  Isao Kohno

IPC分类号： C07K16/18

CPC分类号： G01N33/57438 ,  A61K47/6819 ,  A61K47/6859 ,  A61K49/0032 ,  A61K49/0041 ,  A61K49/0058 ,  A61K51/1057 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

摘要： The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

摘要翻译： 本发明提供了使用血液标记物的胰腺癌的新型诊断或治疗方法。 本发明提供了含有抗AMIGO2抗体的胰腺癌的诊断或治疗药物。

公开(公告)号：US20110117105A1

公开(公告)日：2011-05-19

申请号：US12987814

申请日：2011-01-10

申请人： Milton David GOLDENBERG

发明人： Milton David GOLDENBERG

IPC分类号： A61K39/395 ,  A61P37/02

CPC分类号： G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

摘要： Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

摘要翻译： 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：US20110070156A1

公开(公告)日：2011-03-24

申请号：US12957655

申请日：2010-12-01

申请人： Serengulam V. Govindan ,  David M. Goldenberg

发明人： Serengulam V. Govindan ,  David M. Goldenberg

IPC分类号： A61K51/10 ,  A61K39/395 ,  A61K38/21 ,  A61P35/00 ,  C07K16/46

CPC分类号： A61K51/1057 ,  A61K31/4745 ,  A61K31/7068 ,  A61K39/39558 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/643 ,  A61K47/6803 ,  A61K47/6857 ,  A61K47/6859 ,  A61K51/08 ,  A61K51/109 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/77 ,  A61K2300/00

摘要： Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.

摘要翻译： 本文描述了使用放射性核素 - 抗体缀合物（用于RAIT）和药物 - 抗体缀合物（ADC）的组合物和方法。 RAIT和ADC的组合比单独的RAIT，单独的ADC或RAIT和ADC的影响的总和更有效。 意外的协同作用导致肿瘤生长速度降低和存活率增加，裸鼠中Capan-1人胰腺癌异种移植物的无瘤生存率高。